ObsEva Stock Flies Amid FDA Approval Expectation

Obseva SA, a bio company announces today NDA for linzagolix. Linzagolix is a novel drug candidate that has a unique profile designed to address the needs of premenopausal women with uterine fibroids. The company believes that this drug will be the first and only treatment that can provide flexible dosing options for these patients. OBSV stock surges 17% in the pre-market today. It trades at $2.73 for a share as of pre-market. It jumped from $2.32. FDA is expected to approve this NDA from OBSEVA in Q4. The studies are designed to make the treatment more secure and safe. The directors are really excited to deliver the treatment to the market.

Linzagolix is a unique treatment option for women with uterine fibroids. Its unique dosing options allow for the most effective and safe treatment of these debilitating conditions. The European Medicine Agency has validated the marketing authorization application for linzagolix. This approval is expected in Q4 2021. ObsEva SA is a bio company specializing in producing drugs for pregnant women having issues during that time. Its pipeline includes products for the treatment of pain, heavy menstrual bleeding, and preterm labor. The company started its operations in 2012 in Geneva.